MedTrace Logo

Palbociclib After CDK and Endocrine Therapy (PACE)

NCT03147287 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-09-29

Study results available
· View outcomes & findings →

Summary

This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab

Conditions

Interventions

DRUG

Palbociclib

Palbociclib is a drug that may stop cancer cells from growing

DRUG

Fulvestrant

Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen

DRUG

Avelumab

Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells

Sponsors & Collaborators

Principal Investigators

  • Erica L Mayer, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2022-12-31
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03147287 on ClinicalTrials.gov